Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
Review
Overview
abstract
Pharmacologic inhibition of the Bcr-Abl tyrosine kinase in human chronic myeloid leukemia leads to dramatic clinical responses, but relapses occur in advanced stage patients. New findings about Abl kinase domain regulation provide insight into novel strategies for targeted therapy.
